Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Hinge Health Inc. Class A Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33 (market cap $2.93B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.9× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FNGU | HNGE | |
|---|---|---|
Market Cap | $2.93B | $8.47B |
Volume | 5,898,696 | 1,624,526 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $105.14 |
52-Week Low | $13.73 | $31.17 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.
The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
